188 related articles for article (PubMed ID: 12783198)
1. The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH.
Flowers JL; Hoffman RM; Driscoll TA; Wall ME; Wani MC; Manikumar G; Friedman HS; Dewhirst M; Colvin OM; Adams DJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):253-61. PubMed ID: 12783198
[TBL] [Abstract][Full Text] [Related]
2. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
3. Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient.
Adams DJ; Wahl ML; Flowers JL; Sen B; Colvin M; Dewhirst MW; Manikumar G; Wani MC
Cancer Chemother Pharmacol; 2006 Jan; 57(2):145-54. PubMed ID: 16001167
[TBL] [Abstract][Full Text] [Related]
4. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
5. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
7. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
De Cesare M; Pratesi G; Perego P; Carenini N; Tinelli S; Merlini L; Penco S; Pisano C; Bucci F; Vesci L; Pace S; Capocasa F; Carminati P; Zunino F
Cancer Res; 2001 Oct; 61(19):7189-95. PubMed ID: 11585754
[TBL] [Abstract][Full Text] [Related]
8. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
Mewani RR; Tang W; Rahman A; Dritschilo A; Ahmad I; Kasid UN; Gokhale PC
Int J Oncol; 2004 May; 24(5):1181-8. PubMed ID: 15067340
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
10. Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs.
Conover CD; Greenwald RB; Pendri A; Shum KL
Anticancer Drug Des; 1999 Dec; 14(6):499-506. PubMed ID: 10834271
[TBL] [Abstract][Full Text] [Related]
11. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
12. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
13. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
Song S; Wientjes MG; Walsh C; Au JL
Cancer Res; 2001 Aug; 61(16):6145-50. PubMed ID: 11507065
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
Kurtzberg LS; Roth SD; Bagley RG; Rouleau C; Yao M; Crawford JL; Krumbholz RD; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1029-38. PubMed ID: 19277662
[TBL] [Abstract][Full Text] [Related]
15. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
17. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
Zhang Y; Song S; Yang F; Au JL; Wientjes MG
J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651
[TBL] [Abstract][Full Text] [Related]
18. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.
Osman S; Rowlinson-Busza G; Luthra SK; Aboagye EO; Brown GD; Brady F; Myers R; Gamage SA; Denny WA; Baguley BC; Price PM
Cancer Res; 2001 Apr; 61(7):2935-44. PubMed ID: 11306471
[TBL] [Abstract][Full Text] [Related]
19. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.
Drees M; Dengler WA; Roth T; Labonte H; Mayo J; Malspeis L; Grever M; Sausville EA; Fiebig HH
Clin Cancer Res; 1997 Feb; 3(2):273-9. PubMed ID: 9815683
[TBL] [Abstract][Full Text] [Related]
20. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.
Schluep T; Hwang J; Cheng J; Heidel JD; Bartlett DW; Hollister B; Davis ME
Clin Cancer Res; 2006 Mar; 12(5):1606-14. PubMed ID: 16533788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]